Q1 2025 EPS Estimates for BioMarin Pharmaceutical Inc. Lifted by Zacks Research (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Zacks Research lifted their Q1 2025 EPS estimates for BioMarin Pharmaceutical in a research note issued to investors on Monday, September 16th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $0.59 per share for the quarter, up from their prior estimate of $0.57. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q3 2025 earnings at $0.65 EPS, Q1 2026 earnings at $0.73 EPS and Q2 2026 earnings at $0.80 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, August 5th. The biotechnology company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.39. The business had revenue of $712.03 million for the quarter, compared to analysts’ expectations of $660.51 million. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%.

Several other research firms have also recently issued reports on BMRN. Wells Fargo & Company cut their price objective on shares of BioMarin Pharmaceutical from $115.00 to $90.00 and set an “overweight” rating for the company in a research report on Tuesday. TD Cowen decreased their price target on BioMarin Pharmaceutical from $125.00 to $120.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. JPMorgan Chase & Co. raised their price objective on BioMarin Pharmaceutical from $111.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, September 5th. Evercore ISI upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 6th. Finally, Piper Sandler lifted their price target on shares of BioMarin Pharmaceutical from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Thursday, September 5th. Eight analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.84.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $71.14 on Thursday. The business’s 50 day moving average price is $86.11 and its 200 day moving average price is $84.49. The company has a market cap of $13.51 billion, a price-to-earnings ratio of 66.49, a PEG ratio of 1.03 and a beta of 0.32. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05. BioMarin Pharmaceutical has a one year low of $68.83 and a one year high of $99.56.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new position in BioMarin Pharmaceutical during the 2nd quarter worth approximately $25,000. BOKF NA purchased a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth $31,000. Quent Capital LLC grew its stake in shares of BioMarin Pharmaceutical by 58.9% during the second quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 145 shares in the last quarter. Jones Financial Companies Lllp purchased a new position in BioMarin Pharmaceutical in the fourth quarter valued at $43,000. Finally, Itau Unibanco Holding S.A. purchased a new position in BioMarin Pharmaceutical in the second quarter valued at $47,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.